Last updated: July 6, 2026
Executive summary
Astellas Pharma Inc. v. Cipla Limited (D. Del., No. 1:18-cv-00844) is a U.S. patent infringement case tied to Cipla’s efforts to market a generic version of an Astellas-branded product under the Hatch-Waxman framework. The docket reflects a patent-infringement posture against Cipla’s proposed ANDA launch, with litigation activity organized around claim construction, summary judgment motions, and case management typical of Paragraph IV disputes. The case’s practical outcome for generic entry depends on (i) which asserted patents remained in force through the case and (ii) whether Cipla achieved any favorable rulings that would permit launch earlier than the patent and regulatory exclusivity barriers.
What patents are asserted in Astellas Pharma Inc. v. Cipla Limited 1:18-cv-00844
A complete, claim-level litigation summary requires the asserted-patent list from the complaint and any amended pleadings. A reliable summary depends on the specific patent numbers, their remaining claim scope at the time of judgment, and which patents were stayed, dismissed, or narrowed through motion practice.
Which Astellas patents are commonly asserted in this matter
The asserted patents in Hatch-Waxman disputes targeting ANDA products typically include:
- composition-of-matter patents (active ingredient or key polymorph),
- formulation or dosage-form patents (specific excipients, particle size ranges, or solid-state forms),
- method-of-use patents (indications, dosing regimens),
- and sometimes manufacturing-process patents (specific process steps for a solid form or impurity profile).
A litigation summary that names “composition, formulation, or method-of-use” without the exact patent numbers and asserted claims is not actionable for enforcement strategy, freedom-to-operate analysis, or licensing valuation.
What the docket posture implies
The case caption and number indicate a generic-infringement challenge structure rather than a PTO interference or ITC matter. That posture generally means:
- Cipla filed a Paragraph IV ANDA certification against one or more Astellas-listed Orange Book patents (or a non-infringement/invalidity position in response to those patents),
- Astellas sued within the statutory window after FDA acceptance,
- the action stayed FDA approval pending litigation unless and until a stay was lifted or statutory periods expired.
What is the procedural timeline in 1:18-cv-00844
A docket timeline must be anchored to the dates of:
- complaint filing,
- answer and counterclaims,
- early case management orders,
- claim construction (Markman) hearing date,
- summary judgment or partial summary judgment orders,
- trial date setting and any dispositive rulings,
- any final judgment entry,
- appellate events if any.
A “litigation summary” that omits the date-specific procedural milestones is not usable for patent calendar management or risk modeling.
How strong is Astellas’ patent case in this litigation
A strength analysis depends on:
- claim construction outcomes,
- whether courts narrowed disputed claim terms in a way that aligned with Astellas’ infringement theory,
- whether invalidity arguments (anticipation, obviousness, lack of written description, indefiniteness) survived dispositive motions,
- and whether final rulings granted or denied preliminary injunction relief (rare for ANDA cases post-2018 unless directed to particular products and timelines).
A strength assessment without the court’s orders and holdings is not credible for investment and enforcement decisions.
What to look for in the claim construction record
In Hatch-Waxman cases, patent strength often turns on:
- whether “substantially” or “about” ranges were construed broadly or narrowly,
- whether polymorph/form limitations were enforced,
- whether formulation steps were deemed essential claim limitations,
- whether method-of-use claims required step-by-step performance by the accused party.
What generic entry risks existed for Cipla under 35 U.S.C. § 271(e)(2)
In Paragraph IV disputes, the generic entry risk profile generally follows:
- FDA approval trigger timing (expiration of the relevant patent(s) and exclusivity),
- whether infringement was found for at least one asserted patent,
- whether invalidity was rejected,
- whether any partial victories allowed “carve-outs” that still permit launch.
A “generic entry risk” framework must tie to the actual case outcome (injunction status, final judgment, and any ongoing appeals). Without the disposition, risk cannot be stated.
What Paragraph IV facts matter in 1:18-cv-00844
The key Hatch-Waxman facts include:
- whether Cipla’s ANDA included an IV certification against each Orange Book patent,
- whether any patents were withdrawn, expired, or deemed not infringed,
- whether the asserted patents covered the exact marketed strength and dosage form,
- whether Cipla stipulated non-infringement for certain claims but challenged validity for others.
How does Orange Book status drive this litigation?
For ANDA disputes, Orange Book listing drives:
- the patents subject to the § 271(e)(2) infringement theory,
- the triggering of the statutory 30-month stay after the infringement suit,
- the post-judgment “launch eligibility” timeline.
A litigation analysis that does not identify which Astellas-listed patents were at issue cannot link the docket events to real-world launch dates.
What remedies were sought and what is typical for cases like this
In ANDA cases, plaintiffs typically seek:
- a judgment of infringement,
- a permanent injunction prohibiting FDA approval from leading to commercial launch,
- treble damages and attorney fees under § 284 if willfulness is found (often litigated after liability),
- and sometimes an injunction tied to specific strengths or dosage forms.
A remedies analysis must state whether the court issued a final injunction, whether the case ended in consent judgment, or whether the parties settled.
What happened on settlement, dismissal, or consent judgment
A settlement analysis requires:
- whether the case was dismissed with prejudice,
- whether a consent judgment established effective launch dates,
- whether there were royalty-bearing licenses or covenants not to sue,
- and whether any stipulations were filed around non-infringement or invalidity.
Without the docket disposition, there is no business-grade way to quantify settlement terms.
How to evaluate this case for licensing and freedom-to-operate
For licensing and FTO, the only decision-grade inputs are:
- which patents were asserted,
- the court’s final claim construction,
- and the infringement/validity holdings.
Commercial implications
A case that results in:
- plaintiff victory for at least one asserted patent can block launch until expiry or overcome by design-around,
- defendant victory (invalidation) can open the market for the ANDA product, subject to FDA and regulatory exclusivity,
- settlement with early entry can shift launch timing and create de facto “patent pricing” through royalties or market-sharing.
Key Takeaways
- Astellas Pharma Inc. v. Cipla Limited (1:18-cv-00844) is an ANDA-related Hatch-Waxman patent infringement dispute where the litigation theory is tied to Orange Book-listed patents and Cipla’s Paragraph IV posture.
- A litigation summary suitable for enforcement, licensing, and launch-risk decisions must list the asserted patent numbers, reproduce the court’s claim construction and dispositive holdings, and identify the final judgment or settlement disposition.
- Those decision-grade docket facts are not included in the provided input, so a complete litigation summary cannot be produced from the case caption and number alone.
FAQs
- What does a § 271(e)(2) infringement claim require in ANDA litigation like 1:18-cv-00844?
- How do 30-month stays typically interact with final judgments in Paragraph IV cases?
- What role do claim construction outcomes play in determining infringement of dosage-form limitations?
- How do settlement agreements in Hatch-Waxman cases affect generic launch dates and design-around options?
- What Orange Book changes (withdrawals/expiration) can materially shift litigation value mid-case?
References
- Astellas Pharma Inc. v. Cipla Limited, No. 1:18-cv-00844 (D. Del.).
